The venom directed at proxy advisory firm ISS—and to a lesser extent, its competitor Glass Lewis & Co.—has become so vicious that it now poisons discourse about governance.
Three Myths About ISS
Download the App
The venom directed at proxy advisory firm ISS—and to a lesser extent, its competitor Glass Lewis & Co.—has become so vicious that it now poisons discourse about governance.